Synthesis and antiproliferative evaluation of novel benzoimidazole- contained oxazole-bridged analogs of combretastatin A-4

European Journal of Medicinal Chemistry

Volumn 68, Issue , 2013, Pages 222-232

  Zhou, Jie ^a   Jin, Jing ^a   Zhang, Yi ^a   Yin, Yuwen ^a   Chen, Xiaoguang ^a   Xu, Bailing ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Antiproliferative activity; Benzo d imidazole; Combretastatin; Oxazole; relationship; Structure activity

Indexed keywords

4 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXY 1H BENZO[D] IMIDAZOLE 7YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXY N BENZO[D]IMIDAZOLE 7YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXY N HYDROXYPROPYL BENZO[D]IMIDAZOLE 7YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXY N METHOXYCARBONYL BENZO[D]IMIDAZOLE 7 YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (4 METHOXY N METHYL BENZO [D]IMIDAZOLE 7YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (7 METHOXY N HYDROXYPROPYL BENZO[D]IMIDAZOLE 4YL)OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (7 METHOXY N METHOXYCARBONYL BENZO[D] IMIDAZOLE 4YL) OXAZOLE; 4 (3,4,5 TRIMETHOXYPHENYL) 5 (7 METHOXY N METHYL BENZO[D]IMIDAZOLE 4YL)OXAZOLE; ANTINEOPLASTIC AGENT; COLCHICINE; COMBRETASTATIN A4; IMIDAZOLE DERIVATIVE; NITROGEN; OXAZOLE DERIVATIVE; TUBULIN; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CHEMICAL STRUCTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG BINDING SITE; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; STRUCTURE ACTIVITY RELATION; TUMOR XENOGRAFT;

ANTIPROLIFERATIVE ACTIVITY; BENZO[D]-IMIDAZOLE; COMBRETASTATIN; OXAZOLE; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZIMIDAZOLES; BIBENZYLS; CELL LINE, TUMOR; CELL PROLIFERATION; COMPUTER SIMULATION; FLOW CYTOMETRY; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; OXAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84884495202     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.08.006     Document Type: Article

References (32)

1. G.R. Pettit, S.B. Singh, E. Hamel, C.M. Lin, D.S. Alberts, and D. Garcia-Kendall Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4 Experientia 45 1989 209 211 (Pubitemid 19062390)
2. G.R. Pettit, S.B. Singh, M.R. Boyd, E. Hamel, R.K. Pettit, J.M. Schmidt, and F. Hogan Antineoplastic agents. 291. Isolation and synthesis of combretastatins A-4, A-5, and A-6 J. Med. Chem. 38 1995 1666 1672
3. D.M. Patterson, and G.J.S. Rustin Vascular damaging agents Clin. Oncol. 19 2007 443 456 (Pubitemid 46995617)
4. D.W. Siemann, D.J. Chaplin, and P.A. Walicke A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P) Expert Opin. Invest. Drugs 18 2009 189 197
5. J.W. Lippert Vascular disrupting agents Bioorg. Med. Chem. 15 2007 605 615
6. C.M. Lin, H.H. Ho, G.R. Pettit, and E. Hamel Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin Biochemistry 28 1989 6984 6991 (Pubitemid 19219888)
7. Q. Li, and H.L. Sham Discovery and development of antimitotic agents that inhibit tubulin polymerization for the treatment of cancer Expert Opin. Ther. Pat. 12 2002 1663 1702 (Pubitemid 35355903)
8. A.S. Böhle, I. Leuschner, H. Kalthoff, and D. Henne-Bruns Combretastatin A-4 prodrug: a potent inhibitor of malignant hemangioendothelioma cell proliferation Int. J. Cancer 87 2000 838 843 (Pubitemid 30660564)
9. S.M. Nabha, N.R. Wall, R.M. Mohammad, G.R. Pettit, and A.M. Al-Katib Effects of combretastatin A-4 prodrug against a panel of malignant human B-lymphoid cell lines Anti-Cancer Drugs 11 2000 385 392 (Pubitemid 30459474)
10. C.M.L. West, and P. Price Combretastatin A4 phosphate Anti-Cancer Drugs 15 2004 179 187 (Pubitemid 38429409)
11. G.R. Pettit, B.E. Toki, D.L. Herald, M.R. Boyd, E. Hamel, R.K. Pettit, and J.C. Chapuis Antineoplastic agents. 410. Asymmetric hydroxylation of trans-combretastatin A-4 J. Med. Chem. 42 1999 1459 1465 (Pubitemid 29200882)
12. G.R. Pettit, M.R. Rhodes, D.L. Herald, D.J. Chaplin, M.R. Stratford, E. Hamel, R.K. Pettit, J.C. Chapius, and D. Oliva Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug Anti-Cancer Drug Des. 13 1998 981 993 (Pubitemid 29178769)
13. C. Kanthou, and G.M. Tozer Tumor targeting by microtubule-depolymerising vascular disrupting agents Expert Opin. Ther. Targets 11 2007 1443 1457 (Pubitemid 350200480)
14. Oxigene Company Website, www.oxigene.com, July 2012.
15. H. Katsuyoshi Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism Cancer Metastasis Rev. 31 2012 109 122
16. Aventis Company Website, www.sanofi-aventis.com.
17. www.clinicaltrial.gov.
18. Y. Shan, J. Zhang, Z. Liu, M. Wang, and Y. Dong Development of combretastatin A-4 derivatives as anticancer agents Curr. Med. Chem. 18 2011 523 538
19. M. Marrelli, F. Conforti, G.A. Statti, X. Cachet, S. Michel, F. Tillequin, and F. Menichini1 Biological potential and structure-activity relationships of most recently developed vascular disrupting agents: an overview of new derivatives of natural combretastatin A-4 Cur. Med. Chem. 18 2011 3035 3081
20. N.M. Blanch, G.G. Chabot, L. Quentin, D. Scherman, S. Bourg, and D. Dauzonne In vitro and in vivo biological evaluation of new 4,5-disubstituted 1,2,3-triazoles as cis-constrained analogs of combretastatin A4 Eur. J. Med. Chem. 54 2012 22 32
21. R. Romagnoli, P.G. Baraldi, A. Brancale, A. Ricci, E. Hamel, R. Bortolozzi, G. Basso, and G. Viola Convergent synthesis and biological evaluation of 2-amino-4-(3′,4′,5′-trimethoxyphenyl)-5-aryl thiazoles as microtubule targeting agents J. Med. Chem. 54 2011 5144 5153
22. M. Lee, O. Brockway, A. Dandavati, S. Tzou, R. Sjoholm, V. Satam, C. Westbrook, S.L. Moooberry, M. Zeller, B. Babu, and M. Lee A novel class of trans-methylpyrazoline analogs of combretastatins: synthesis and in-vitro biological testing Eur. J. Med. Chem. 46 2011 3099 3104
23. M. Arthuis, R. Pontikis, G.G. Chabot, L. Quentin, D. Scherman, and J.C. Flornet Domino approach to 2-aroyltrimethoxyindoles as novel heterocyclic combretastatin A4 analogues Eur. J. Med. Chem. 46 2011 95 100
24. G.C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, and A.A. Genazzani Medicinal chemistry of combretastatin A4: present and future directions J. Med. Chem. 49 2006 3033 3044 (Pubitemid 43830499)
25. H.P. Hsieh, J.P. Liou, and N. Mahindroo Pharmaceutical design of antimitotic agents based on combretastatins Curr. Pharm. Des. 11 2005 1655 1677 (Pubitemid 40668143)
26. A. Chaudhary, S.N. Pandeya, P. Kumar, P.P. Sharma, S. Gupta, N. Soni, K.K. Verma, and G. Bhardwaj Combretastatin A-4 analogs as anticancer agents Mini-Rev. Med. Chem. 7 2007 1186 1205 (Pubitemid 350303084)
27. S. Rohit, and K. Harneet Advances in synthetic approaches for the preparation of combretastatin-based anti-cancer agents Synthesis 2009 2009 2471 2491
28. L. Wang, K.W. Woods, Q. Li, K.J. Barr, R.W. McCroskey, S.M. Hannick, L. Gherke, R.B. Credo, Y.H. Hui, K. Marsh, R. Warner, J.Y. Lee, N. Zielinski-Mozng, D. Frost, S.H. Rosenberg, and H.L. Sham Potent, orally active heterocycle-based combretastatin A-4 analogues: synthesis, structure-activity relationship, pharmacokinetics, and in vivo antitumor activity evaluation J. Med. Chem. 45 2002 1697 1711 (Pubitemid 34293536)
29. C. Kanthou, O. Greco, A. Stratford, I. Cook, R. Knight, O. Benzakour, and G. Tozer The tubulin-binding agent combretastatin A-4 phosphate arrests endothelial cells in mitosis and induces mitotic cell death Am. J. Pathol. 165 2004 1401 1411 (Pubitemid 39297744)
30. G. Wu, D.H. Robertson, C.L. Brooks, and M. Vieth Detailed analysis of grid-based molecular docking: a case study of CDOCKER - a CHARMm-based MD docking algorithm J. Comput. Chem. 24 2003 1549 1562
31. R.B.G. Ravelli, B. Gigant, P.A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, and M. Knossow Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain Nature 428 2004 198 202 (Pubitemid 38374318)
32. E.F. Pettersen, T.D. Goddard, C.C. Huang, G.S. Couch, D.M. Greenblatt, E.C. Meng, and T.E. Ferrin UCSF Chimera-A visualization system for exploratory research and analysis J. Comput. Chem. 25 2004 1605 1612